This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rubin, L. J. Search for Related Content PubMed PubMed Citation Articles by Rubin, L. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Pulmonary Hypertension Related Collections Pulmonary circulation and disease Endothelium/vascular type/nitric oxide

(Circulation. 2006;114:1350-1351.)
© 2006 American Heart Association, Inc.

Editorial

Endothelin-1 and the Pulmonary Vascular Response to Altitude

A New Therapeutic Target?

Lewis J. Rubin, MD

From the Division of Pulmonary and Critical Care Medicine, University of California at San Diego.

Correspondence to Dr Lewis J. Rubin, Division of Pulmonary and Critical Care Medicine, University of California at San Diego, 9300 Campus Point Dr, M/C 7381, La Jolla, CA 92037-1300. E-mail ljrubin@ucsd.edu

Key Words: Editorials • edema • endothelin • hypoxia • pulmonary heart disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Ascent to high altitude is normally associated with a modest increase in pulmonary artery pressure.¹ The increased right ventricular afterload, coupled with hypobaric hypoxia-induced reductions in blood oxygen content, may lead to diminished peripheral oxygen delivery and result in dyspnea, fatigue, and exercise intolerance.² The predominant mechanism responsible for the increase in pulmonary artery pressure at altitude is hypoxic pulmonary vasoconstriction, which is mediated through an oxygen-sensitive pulmonary artery smooth muscle cell voltage-gated K⁺ channel.³ The primary site of hypoxic pulmonary vasoconstriction is the small (50 to 200 µm) muscular pulmonary arteries, although the pulmonary venous circuit may contribute up to 20% of the pressor response.⁴ A more clinically significant and potentially fatal cardiovascular consequence of exposure to altitude is the development of high-altitude pulmonary edema (HAPE). Risk factors for HAPE include gender, rate of altitude ascent, recent respiratory infection, and prior acclimatization⁵; a genetic susceptibility also has been suggested.⁶ Although the mechanisms responsible for the development of HAPE remain unclear, it is associated with greater increases in pulmonary artery pressure and increased pulmonary capillary pressure, which results in hydrostatic pulmonary edema.⁷ The increased capillary pressure despite normal left ventricular function suggests that an exaggerated pulmonary venoconstrictor response may play a critical role. A variety of vasoactive substances are elaborated in the pressor response to altitude and in particular HAPE, including endothelin-1 (ET-1), a potent pulmonary arterial and venous constrictor.⁸ In this issue of Circulation, Modesti and colleagues⁹ provide further evidence of the contribution of ET-1 to the . . . [Full Text of this Article]